Radiation Oncology

Radiation Oncology

Biological, Physical and Clinical Aspects

The course provides an overview of (1) radiobiological and physical principles of radiation oncology (2) technical innovation in precision radiotherapy (3) the route of the radiotherapy patient – via diagnosis, imaging and treatment planning – to therapy.

Topics that will be addressed: effects of irradiation on the DNA and cellular level; radiation response of tumours and normal tissues; physics of modern conformal radiotherapy; imaging; treatment planning; fractionation and hypofractionation; particle irradiation; image-guided radiotherapy; brachytherapy; radiotherapy in combination with chemotherapy, targeted agents, hyperthermia and immunotherapy; treatment of breast cancer, lung cancer, gynaecological and head & neck tumours; quality of life and late effects. New and exciting developments in radiation oncology will be addressed.

The course encompasses three practical trainings: (1) the radiobiology laboratory (2) computer-based target volume delineation (3) patient treatment simulation on a linear accelerator. In addition, three PhD students will be invited to give an overview about their research project.

Date and time:
Target audience


Registration deadline

March 25 – 29 2019,  9:00 – 17:00h
OOA PhD students, researchers and trainees in oncology with biological, clinical or physics background, having particular interest in the principles and therapeutic effects of radiation.
Peter Sminia, Jan-Jakob Sonke, Lukas Stalpers

Free of charge (coffee/tea and drinks on friday included)
Registration is closed


OOA course May 20-24, 2019 NKI

Epigenetics and epitranscriptomics: from mechanism to cancer

Fred van Leeuwen & Reuven Agami

General program
– Monday: introduction/self study/preparation (till 13:00 hours)
– Tue: no program
– Wed: journal clubs and paper reviews (till 16:00 hours)
– Thu: journal clubs and paper reviews (till 16:00 hours)
– Friday: symposium and  lunch with the speaker. For program of the symposium,  click here

The course is closed for registration

8 International Leading Experts

Clodagh O’Shea
Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies. https://www.salk.edu/scientist/clodagh-oshea       

Johannes Zuber
Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna

Jason W. Locasale
Duke University School of Medicine

Gideon Rechavi
Sheba Cancer Research Center; Tel Aviv University

Petra Hajkova, ICL
MRC London Institute of Medical Sciences; Imperial College London

Sohail Tavazoie
Laboratory of Systems Cancer Biology, The Rockefeller University

Chuan He
Department of Chemistry, University of Chicago

Richard Flavell
HHMI; Department of Immunobiology, Yale School of Medicine

Some of the topics to be covered
Metabolism and epigenetics, cancer dependencies, cutting edge ‘epi’technologies, tRNAs in cancer, mRNA modifications, DNA (hydroxy)methylation, immune cell programming, 3D chromatin structure, epigenetic reprogramming.

Biobusiness course

Ever thought of starting a company based on your research results? Or patenting your own research data? This is possible! This course shows you how. When scientific discoveries are developed for commercial application, success of entry into the market is dependent on many factors. Among these are intellectual property, indication selection, (pre)clinical testing and financial aspects.
This 2-week course is to get Master’s and PhD students familiar with the ideas and concepts behind the valorization of research ideas and technology. The course will give insights in the identification of research or research ideas that can be commercialized, performance of proof-of-concept validation, the road through patent protection of obtained results or technology, pre-seed financing of research, formation of a start-up company and the development of a product into the market. There will be seminars by a selection of top-notch speakers, ranging from researchers with starting spin-off companies, experts on grant writing, patenting, regulatory issues, as well as finance and venture capital, to captains of industry and CEOs of large and successful companies.

Questions that will be addressed are:
• What are the many factors involved in getting laboratory discovery to a novel approved medicine?
• How does big pharma and biotech industry access innovation?
• How do entrepreneurial universities contribute to innovation?
• Which party plays which role at all stages?
• What are the keys to success?

There will be 24 contact hours, including lectures, lecture repetitions and discussions by the course coordinators and a number of invited lecturers. These will include external experts on molecular diagnostics and regulatory affairs, VUmc colleagues with presentations on their own spin-off companies, and colleagues of the Technology Transfer Office on legal and patent issues. In addition, the course consists of independent learning on the basis of exploring literature and business reports on selected topics. All lectures will be preceded by formulation of expectations and followed by lecture repetition sessions. Next to classes and discussion sessions, there will be six assignments to elaborate in groups of 4-5 students. Reporting will take place by dedicated presentations or written reports. On the last day of the course, students will present a business plan for a start-up company.
There is a requirement for 90% attendance. There is no general exam.

Date: October 29 – November 9, 2018
ECTS: 3.0
Location: VUmc
Target audience: PhD students in oncology AMC, VUmc and NKI
Price: Free of charge
Organization: Prof. dr. Arjan Griffioen, Dr. Else Huijbers, Dr. Judy van Beijnum
Information: For any questions or need for extra information please contact aw.griffioen@vumc.nl
Registration: This course is closed for registration